Back to search results

TAPUR Study: Targeted Drugs for Advanced Cancers

This study, called TAPUR, is looking at how well certain FDA-approved drugs work for people with advanced cancer (solid tumors, multiple myeloma, or non-Hodgkin lymphoma) that is no longer responding to standard treatments. The drugs being studied include Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, and Vemurafenib and Cobimetinib. The goal is to see if these drugs can shrink tumors or stop them from growing, which is measured after 16 weeks of treatment. You may be able to join if you are 12 years or older and your tumor has a specific genetic change that these drugs are designed to target. The study aims to enroll 4200 participants, but its current status is unclear.

Study design
This is a non-randomized study that aims to enroll 4200 participants. It is looking at the safety and effectiveness of targeted cancer drugs.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for measuring treatment success is assessed at 16 weeks of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02693535

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
PHASE2Ages 12+InterventionalTreatment
American Society of Clinical Oncology
~4,200 participants
Updated 2026-09-01 on ClinicalTrials.gov
What's tested:SunitinibTemsirolimusTrastuzumab and PertuzumabVemurafenib and CobimetinibOlaparibNivolumab and Ipilimumab

At a glance

Recruiting sites
153 of 181 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Measured over Assessed at 16 weeks of treatment

Conditions

Lymphoma, Non-Hodgkin
Multiple Myeloma
Advanced Solid Tumors

Explore related trials

B-Cell Non-Hodgkin LymphomaMultiple MyelomaSolid Neoplasm

NCT02693535

Where you'd take part

This study runs at 181 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Atrium Health's Levine Cancer Institute

    Charlotte, North Carolinastudy coordinator listed

    Recruiting

  • Aurora Bay Area Medical Center

    Marinette, Wisconsinstudy coordinator listed

    Recruiting

  • Aurora BayCare Medical Center

    Green Bay, Wisconsinstudy coordinator listed

    Recruiting

  • Aurora Cancer Care - Burlington

    Burlington, Wisconsinstudy coordinator listed

    Recruiting

  • Aurora Cancer Care - Grafton

    Grafton, Wisconsinstudy coordinator listed

    Recruiting

  • Aurora Cancer Care - Kenosha South

    Kenosha, Wisconsinstudy coordinator listed

    Recruiting

  • Aurora Cancer Care - Milwaukee West

    Wauwatosa, Wisconsinstudy coordinator listed

    Recruiting

  • Aurora Cancer Care - Racine

    Racine, Wisconsinstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Laurie Smith, MA
[email protected]
www.tapur.org
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

12 years of age or older (\*Restrictions apply. Not all therapies are available for patients \<18)
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
Ability to understand and the willingness to sign a written informed consent/assent document.
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.

Exclusion

Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.

What this trial measures

  • Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteriaAssessed at 16 weeks of treatment

    Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.